Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Thom Bunnell

Internal Medicine Lawrenceburg, IN Doctor of Osteopathy

NPI 1093754640 CMS profile 49793

98 Elm St, Lawrenceburg, IN 47025

Open in the dashboard

General payments

$10,235

628 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Thom Bunnell of Lawrenceburg, IN is reported in the CMS Open Payments database as having received $10,235 across 628 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,739 93
2024 General $2,054 109
2023 General $1,925 119
2022 General $1,501 101
2021 General $1,622 109
2020 General $465 34
2019 General $928 63

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Thom Bunnell
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Thom Bunnell were reported at $1,739. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Thom Bunnell Internal Medicine median Middle half National median
2019 $928 $159 $48–$570 $163
2020 $465 $119 $33–$402 $114
2021 $1,622 $135 $37–$521 $132
2022 $1,501 $141 $42–$496 $149
2023 $1,925 $149 $45–$519 $160
2024 $2,054 $154 $47–$537 $164
2025 $1,739 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,430 95 payments
  2. Pfizer Inc. $1,068 74 payments
  3. Novo Nordisk Inc $914 65 payments
  4. AstraZeneca Pharmaceuticals LP $887 31 payments
  5. GlaxoSmithKline, LLC. $655 44 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $539 36 payments
  7. Astellas Pharma US Inc $492 21 payments
  8. Abbott Laboratories $393 21 payments
  9. Amgen Inc. $345 23 payments
  10. Merck Sharp & Dohme Corporation $323 23 payments
  11. Other $3,189 195 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $10,107 625 payments
  2. Education $128 3 payments
Products named General payments · program years 2019–2025
  1. VRAYLAR $689 40 payments
  2. ELIQUIS $641 41 payments
  3. Ozempic $594 49 payments
  4. RYBELSUS $571 47 payments
  5. FARXIGA $518 8 payments
  6. NURTEC ODT $432 26 payments
  7. TRELEGY ELLIPTA $413 29 payments
  8. UBRELVY $328 26 payments
  9. FreeStyle Libre 3 $325 17 payments
  10. Veozah $322 15 payments
  11. Other $9,567 601 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 263 drugs

Part D claims

28,209

Median for Internal Medicine: 777

Drug cost

$1,746,052

Median for Internal Medicine: $73,373

Branded share of claims

24.1%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 578 $233,166
Mounjaro Tirzepatide Brand 144 $160,081
Farxiga Dapagliflozin Propanediol Brand 239 $121,469
Ozempic Semaglutide Brand 80 $108,463
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 95 $98,074
Myrbetriq Mirabegron Brand 157 $78,617
Rexulti Brexpiprazole Brand 24 $58,078
Jardiance Empagliflozin Brand 46 $54,438
Xarelto Rivaroxaban Brand 91 $52,869
Vraylar Cariprazine Hcl Brand 36 $51,869

The 10 drugs with the highest cost, of 263 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 50 billing codes

Paid by Medicare

$139,628

Of which drugs: $23,517

Medicare patients

512

Average age 76

Services billed

3,279

289 women, 223 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 45%
Depression 39%
Diabetes 32%
Ischemic heart disease 28%
Chronic kidney disease 25%
Heart failure 19%
Atrial fibrillation 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Sarscv2 vac 30mcg trs-suc im 91320 Office 69 72 $10,104
Vaccine for influenza for injection into muscle 90662 Office 120 120 $9,573
Pcv20 vaccine im 90677 Office 11 11 $3,139
Vaccine for influenza for administration into muscle, 0.5 ml dosage 90686 Office 17 17 $350
Injection, methylprednisolone acetate, 1 mg J1010 Office 12 600 $49

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 41 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $224
$224 36 —
Veozah
  • Astellas Pharma US Inc $152
$152 17 —
JARDIANCE
  • Lilly USA, LLC $64
  • Boehringer Ingelheim Pharmaceuticals, Inc. $63
$127 46 —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $69
  • Lundbeck LLC $51
$120 24 —
Wegovy
  • Novo Nordisk Inc $89
$89 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 41 with Patron

Records

628 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record